The Combination Therapy, is under therapeutic study with IRB approval from the DCG (India), IECP, (India), that is an investigation into the combination treatment of both of the vasculature and central nervous system of an MS patient with adult autologous stem cells (cells taken from the patient). It is a novel, innovative ‘case study series’ entitled ‘Intravenous and Intrathecal Implantation of Adult Autologous Stem Cells for Patients with Multiple Sclerosis and Other Neurodegenerative Diseases’. Based on what has been established as evidence in previous investigations into neurodegenerative diseases through clinical trials, this protocol was developed over several years, 2009 through 2011.
Regenetek Research has taken a novel approach that has had a significant and real effect on the disease. Depending on the stage of the disease, significant effect would mean halting the disease process and/or repairing the damage to the nervous system. Understanding the disease trigger is the first step to developing an effective treatment strategy and to do this, we have used existing clinical studies that have determined the cause of chronic inflammation in the brain.
The Regenetek study recognizes that MS is an autoimmune CNS specific disorder. An analysis of spinal fluid reveals certain proteins associated with both the presence of, and the current intensity of the disease activity. A direct link can be made between the dysfunction in MS which is either cognitive, or manifests itself in the form of pathological degrees of weakness, spasticity, bowel and bladder dysfunction as well as paralysis that is a result of spinal cord disease.
…….
Share our Articles with others
